Multiple sclerosis: Advances in understanding, diagnosing, and treating the underlying disease

Robert J. Fox, MD
Medical Director, Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, The Cleveland Clinic Foundation; Cleveland Clinic Lerner School of Medicine, Case Western Reserve University, Cleveland

Francois Bethoux, MD
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, The Cleveland Clinic Foundation

Myla D. Goldman, MD
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, The Cleveland Clinic Foundation

Jeffrey A. Cohen, MD
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, The Cleveland Clinic Foundation

Address: Robert J. Fox, MD, Mellen Center, U10, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail foxr@ccf.org

Dr. Fox has indicated that he has served as a consultant or lecturer for the Accorda Therapeutics, Biogen Idec, Genentech, Merck, Questor Pharmaceuticals, Serono, and Teva Neuroscience corporations.

Dr. Bethoux has indicated that he has served as a lecturer for the Biogen Idec corporation.

Dr. Cohen has indicated that he has served as a consultant for the Biogen Idec and Teva Neuroscience corporations and has received research support from the Biogen Idec corporation.

This work was supported by grants from the National Institutes of Health (NINDS K23 NS 47211 to RJF), National MS Society (RG 33548A2 to RJF, FP 1521-A-1 to MDG), the Nancy Davis Center Without Walls (RJF and JAC), and Potiker Fellowship (MDG).

Robert J. Fox, MD
Medical Director, Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, The Cleveland Clinic Foundation; Cleveland Clinic Lerner School of Medicine, Case Western Reserve University, Cleveland

Francois Bethoux, MD
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, The Cleveland Clinic Foundation

Myla D. Goldman, MD
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, The Cleveland Clinic Foundation

Jeffrey A. Cohen, MD
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, The Cleveland Clinic Foundation

Address: Robert J. Fox, MD, Mellen Center, U10, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail foxr@ccf.org

Dr. Fox has indicated that he has served as a consultant or lecturer for the Accorda Therapeutics, Biogen Idec, Genentech, Merck, Questor Pharmaceuticals, Serono, and Teva Neuroscience corporations.

Dr. Bethoux has indicated that he has served as a lecturer for the Biogen Idec corporation.

Dr. Cohen has indicated that he has served as a consultant for the Biogen Idec and Teva Neuroscience corporations and has received research support from the Biogen Idec corporation.

This work was supported by grants from the National Institutes of Health (NINDS K23 NS 47211 to RJF), National MS Society (RG 33548A2 to RJF, FP 1521-A-1 to MDG), the Nancy Davis Center Without Walls (RJF and JAC), and Potiker Fellowship (MDG).

Robert J. Fox, MD
Medical Director, Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, The Cleveland Clinic Foundation; Cleveland Clinic Lerner School of Medicine, Case Western Reserve University, Cleveland

Francois Bethoux, MD
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, The Cleveland Clinic Foundation

Myla D. Goldman, MD
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, The Cleveland Clinic Foundation

Jeffrey A. Cohen, MD
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, The Cleveland Clinic Foundation

Address: Robert J. Fox, MD, Mellen Center, U10, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail foxr@ccf.org

Dr. Fox has indicated that he has served as a consultant or lecturer for the Accorda Therapeutics, Biogen Idec, Genentech, Merck, Questor Pharmaceuticals, Serono, and Teva Neuroscience corporations.

Dr. Bethoux has indicated that he has served as a lecturer for the Biogen Idec corporation.

Dr. Cohen has indicated that he has served as a consultant for the Biogen Idec and Teva Neuroscience corporations and has received research support from the Biogen Idec corporation.

This work was supported by grants from the National Institutes of Health (NINDS K23 NS 47211 to RJF), National MS Society (RG 33548A2 to RJF, FP 1521-A-1 to MDG), the Nancy Davis Center Without Walls (RJF and JAC), and Potiker Fellowship (MDG).